Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| GANX | 8-K | bullish | 6/10 | Gain Therapeutics announced long-term open-label extension data from its Phase 1b study of rexaceract in Parkinson's dis | Oct 1, 2026 |
| BCDA | 8-K | neutral | 4/10 | BioCardia filed a revised De Novo pre-submission with the FDA CDRH for its Helix Catheter, a device for therapeutic and | Oct 1, 2026 |
| APUS | 8-K | neutral | 2/10 | Apimeds Pharmaceuticals US, Inc. disclosed the resignation of Interim CFO Erick Frim effective September 29, 2026, and t | Oct 1, 2026 |
| BCDA | PRESS-RELEASE | bullish | 7/10 | BioCardia announced it has completed a revised De Novo pre-submission to the FDA's CDRH for its Helix Catheter, a device | Oct 1, 2026 |
| DARE | 8-K | neutral | 2/10 | Dare Bioscience filed an 8-K on October 1, 2026, to furnish a corporate investor presentation (Exhibit 99.1) under Item | Oct 1, 2026 |
| REGN | ANALYST-UPGRADE | bullish | 4/10 | Argus Research issued a double upgrade on Regeneron Pharmaceuticals (REGN) on October 1, 2026, raising its rating from H | Oct 1, 2026 |
| VIR | 8-K | neutral | 2/10 | Vir Biotechnology appointed Aziz Sawaf as Executive Vice President and CFO, effective October 5, 2026, replacing interim | Oct 1, 2026 |
| TOMZ | PRESS-RELEASE | neutral | 3/10 | TOMI Environmental Solutions announced growing adoption of its SteraMist iHP technology in India's pharmaceutical sector | Oct 1, 2026 |
| IMNM | ANALYST-UPGRADE | bearish | 4/10 | Stifel initiated coverage on Immunome Inc. (IMNM) with a Hold rating and a $24 price target on October 1, 2026. The firm | Oct 1, 2026 |
| AZTR | 8-K | neutral | 4/10 | Azitra announced that its Phase 1/2 trial of ATR-04 for EGFR inhibitor-associated skin rash has cleared the safety revie | Oct 1, 2026 |
| GEVO | PRESS-RELEASE | bullish | 5/10 | Gevo sold substantially all of its 2026 Section 45Z tax credits for $70 million, receiving over $30 million in cash thro | Oct 1, 2026 |
| HRMY | PRESS-RELEASE | neutral | 3/10 | Harmony Biosciences announced a poster presentation at the 17th European Narcolepsy Days featuring data from its ongoing | Oct 1, 2026 |
| CADL | PRESS-RELEASE | bullish | 7/10 | Candel Therapeutics announced peer-reviewed publication of final Phase 2a data for aglatimagene besadenovec plus valacyc | Oct 1, 2026 |
| EVMN | 8-K | bullish | 7/10 | Evommune presented late-breaking Phase 2a proof-of-concept data for EVO301 in atopic dermatitis at the EADV 2026 Congres | Oct 1, 2026 |
| ALLR | 8-K | neutral | 3/10 | Allarity Therapeutics issued a press release highlighting recent advances in its Drug Response Predictor (DRP) technolog | Oct 1, 2026 |
| RADX | 6-K | neutral | 2/10 | Radiopharm Theranostics filed a 6-K reporting the expiry of 24 million unlisted options held by director Riccardo Caneva | Oct 1, 2026 |
| NKTR | 8-K | bullish | 6/10 | Nektar Therapeutics presented new Phase 2b data for rezpegaldesleukin at EADV 2026, showing durable and deepening respon | Oct 1, 2026 |
| GLUE | 8-K | bullish | 7/10 | Monte Rosa Therapeutics reported positive Phase 1 data for MRT-8102, a NEK7-directed molecular glue degrader, showing ro | Oct 1, 2026 |
| ABUS | SC TO-I/A | bullish | 6/10 | Arbutus Biopharma completed its modified Dutch auction tender offer, purchasing 46 million shares (23% of outstanding) f | Oct 1, 2026 |
| KYNB | 8-K | neutral | 2/10 | Kyntra Bio appointed Andrew E. Singer as a Class III director and Audit Committee member effective October 1, 2026, repl | Oct 1, 2026 |
| ABUS | PRESS-RELEASE | bullish | 7/10 | Arbutus Biopharma completed a modified Dutch auction tender offer, repurchasing 46 million shares for $230 million at $5 | Oct 1, 2026 |
| IFRX | PRESS-RELEASE | neutral | 2/10 | InflaRx announced the appointment of Dr. Gabriela Alperovich as SVP & Global Head of Clinical Development, effective Oct | Oct 1, 2026 |
| FHTX | 8-K | bearish | 7/10 | Foghorn Therapeutics is discontinuing its Phase 1 trial of FHD-909 (SMARCA2 degrader) and the broader collaboration with | Oct 1, 2026 |
| GENB | PRESS-RELEASE | bullish | 5/10 | Generate Biomedicines announced the first patient dosed in a Phase 1 trial of GB-5267, an AI-designed IL-18 armored CAR | Oct 1, 2026 |
| FATE | PRESS-RELEASE | neutral | 2/10 | Fate Therapeutics announced management participation in Q4 2026 investor conferences. No financial results or material b | Oct 1, 2026 |
| KLRA | PRESS-RELEASE | neutral | 4/10 | Kailera Therapeutics presented Phase 1 data at EASD 2026 showing ribupatide injection is bioequivalent across abdomen, u | Oct 1, 2026 |
| AGMB | 6-K | bullish | 7/10 | Agomab reported positive topline data from the 48-week open-label extension (OLE) of the Phase 2a STENOVA trial for ontu | Oct 1, 2026 |
| AGMB | PRESS-RELEASE | bullish | 7/10 | Agomab announced positive 48-week open-label extension (OLE) results from the Phase 2a STENOVA trial of ontunisertib in | Oct 1, 2026 |
| CUVL | 6-K | neutral | 3/10 | Clinuvel Pharmaceuticals announced that new patient cases from its CUV105 trial of SCENESSE (afamelanotide) with NB-UVB | Oct 1, 2026 |
| REGN | PRESS-RELEASE | bullish | 7/10 | Regeneron and Sanofi expanded their long-standing antibody collaboration, adding four next-generation long-acting antibo | Oct 1, 2026 |